Flash Finance

Suraksha Diagnostic LimitedSURAKSHACorporate

Healthcare Latest results: Jun 2026 12 quarters of data
Consolidated Standalone
₹306.70
MCap ₹1,597 Cr · P/E 45.5
Suraksha Diagnostic Limited — Stock analysis & AI research Suraksha Diagnostic Limited — Multibagger AI analysis Suraksha Diagnostic Limited — Seasonality — best & worst months Suraksha Diagnostic Limited — Technical indicators & charts Suraksha Diagnostic Limited — Technical setup — score, trend, support & resistance Suraksha Diagnostic Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹88 Cr
Sales · Jun 2026
+20.7% YoY
₹30 Cr
Operating Profit · Jun 2026
+28.2% YoY
34.7%
OPM % · Jun 2026
+6.1% YoY
₹13 Cr
Net Profit · Jun 2026
+40.0% YoY
₹2.50
EPS · Jun 2026
+38.9% YoY

📝 Suraksha Diagnostic Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Suraksha Diagnostic Limited reported revenue of ₹88 crore for the quarter ended June 2026 (Q1 FY27), up 20.7% from ₹73 crore in the same quarter last year, and up 7.7% sequentially over the March 2026 quarter.

Net profit rose 40.0% year-on-year to ₹13 crore, from ₹9 crore. Earnings per share (EPS) came in at ₹2.50.

Operating profit stood at ₹30 crore — an operating margin (OPM) of 34.7%, compared with 32.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Suraksha Diagnostic Limited posted revenue of ₹310 crore, a growth of 23.1% over FY25, with a net profit of ₹31 crore (up 1.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹325 crore with a net profit of ₹35 crore.

Valuation snapshot

At the current price of ₹306.70, SURAKSHA has a market capitalisation of ₹1,597 crore and a trailing P/E of about 45.5.

Within the Healthcare industry, it is the 10th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 49.10%, foreign institutional investors (FIIs) 13.97%, domestic institutional investors (DIIs) 21.56%, public shareholders 15.37% of Suraksha Diagnostic Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,597 Cr
Current Price ?
₹306.7
P/E ?
45.54above ind
Industry P/E ?
34.70
P/B ?
6.55
P/S ?
4.91
P/FCF ?
106.49
Enterprise Value ?
₹1,727 Cr
EV/EBITDA ?
16.92
PEG ?
0.75
Earnings Yield ?
3.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹325 Cr
OPM ?
31.4%
Profit after tax (TTM) ?
₹35 Cr
EPS (TTM) ?
₹6.73
ROCE ?
17.0%
ROE ?
14.4%
ROA ?
7.8%
Growth
Sales — latest qtr ?
₹88 Cr
PAT — latest qtr ?
₹13 Cr
YoY qtr sales growth ?
20.7%
YoY qtr profit growth ?
40.0%
Sales growth (3y) ?
18%
Sales growth (5y) ?
17%
Profit growth (3y) ?
61%
Profit growth (5y) ?
32%
Financial Health
Debt ?
₹130 Cr
Debt to Equity ?
0.53
Interest Coverage ?
4.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.10%
Change in promoter holding ?
0.21%
Pledged percentage ?
N/A
Market
Return 3 months ?
18.4%
Return 6 months ?
8.5%

🗓️ Quarterly results (12 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 605255616760657379788188 +20.7% +7.7%
Operating Profit 211519212318192424232430 +28.2% +24.9%
Other Income 110111111111 +20.1% +37.7%
Interest 222222233344 +37.6% -5.0%
Depreciation 8889999910111111 +19.0% +0.2%
Profit Before Tax 11691114891212101017 +32.5% +65.6%
Net Profit 85681067997613 +40.0% +108.5%
EPS 121.8867.3994.491.841.941.181.421.801.731.441.212.50 +38.9% +106.6%
OPM % 34.7% 29.6% 35.3% 33.9% 34.7% 30.7% 29.5% 32.7% 30.6% 29.8% 29.9% 34.7% +6.1% +16.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹252 Cr ₹310 Cr ₹325 Cr +23.1%
Operating Profit ₹81 Cr ₹95 Cr ₹102 Cr +17.4%
OPM % 32.23% 30.73% 31.37% -4.7%
NPM % 12.29% 10.12% 10.78% -17.7%
Other Income ₹4 Cr ₹3 Cr ₹3 Cr -17.8%
Depreciation ₹35 Cr ₹41 Cr ₹43 Cr +17.4%
Interest ₹8 Cr ₹13 Cr ₹14 Cr +49.8%
EBIT ₹46 Cr ₹54 Cr ₹59 Cr +17.4%
PBT ₹41 Cr ₹45 Cr ₹49 Cr +7.6%
Tax ₹8 Cr ₹3 Cr ₹4 Cr -56.6%
Net Profit ₹31 Cr ₹31 Cr ₹35 Cr +1.4%
EPS ₹6.38 ₹6.18 ₹6.88 -3.1%
Material Cost ₹23 Cr ₹9 Cr ₹10 Cr -61.8%
Employee Cost ₹33 Cr ₹13 Cr ₹14 Cr -60.7%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 771010 +0.0%
Reserves 147171201234 +16.4%
Borrowings 999289130 +46.1%
Other Liabilities 28303373 +121.2%
Total Liabilities 281300334448 +34.1%
Fixed Assets 195212223316 +41.7%
CWIP 211135 +218.2%
Investments 0010 -100.0%
Other Assets 84879997 -2.0%
Total Assets 281300334448 +34.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 44606382 +30.2%
Cash from Investing Activity -21-35-40-52 -30.0%
Cash from Financing Activity -24-25-24-29 -20.8%
Net Cash Flow -10-01 —
Free Cash Flow 32182115 -28.6%
CFO/OP 109%95%90%100% +11.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 9152027 +35.0%
Inventory Days 828910081 -19.0%
Days Payable 187193169209 +23.7%
Cash Conversion Cycle -96-89-49-101 -106.1%
Working Capital Days -49-37-23-28 -21.7%
ROCE % 9%17%18%17% -5.6%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 48.89%48.98%49.00%49.10%49.10%49.10% +0.0%
FIIs 13.95%13.73%13.46%13.46%13.47%13.97% +3.7%
DIIs 22.37%21.98%22.57%23.14%23.23%21.56% -7.2%
Public 14.79%15.30%14.98%14.31%14.21%15.37% +8.2%
No. of Shareholders 79,67075,30470,96367,10764,86660,792 -6.3%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Suraksha Diagnostic Limited's revenue in Q1 FY27?
Suraksha Diagnostic Limited reported revenue of ₹88 crore for the quarter ended June 2026 (Q1 FY27), up 20.7% from ₹73 crore in the same quarter last year, and up 7.7% sequentially over the March 2026 quarter.
What was Suraksha Diagnostic Limited's net profit in Q1 FY27?
Net profit rose 40.0% year-on-year to ₹13 crore, from ₹9 crore. Earnings per share (EPS) came in at ₹2.50.
What is SURAKSHA's market capitalisation and P/E ratio?
At the current price of ₹306.70, SURAKSHA has a market capitalisation of ₹1,597 crore and a trailing P/E of about 45.5.
Who owns Suraksha Diagnostic Limited? (shareholding pattern)
As of Sep 2026, promoters held 49.10%, foreign institutional investors (FIIs) 13.97%, domestic institutional investors (DIIs) 21.56%, public shareholders 15.37% of Suraksha Diagnostic Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI